96 related articles for article (PubMed ID: 36802389)
1. Role of Mismatch Repair Deficiency Status and Microsatellite Instability in Relation to the Expression of Immune Checkpoint Proteins in Colorectal Cancer.
Sharma A; Raphael V; Lyngdoh BS; Harris C; Jagtap VK
Cureus; 2023 Aug; 15(8):e43571. PubMed ID: 37719521
[TBL] [Abstract][Full Text] [Related]
2. Microsatellite Instability and Immune Response: From Microenvironment Features to Therapeutic Actionability-Lessons from Colorectal Cancer.
Greco L; Rubbino F; Dal Buono A; Laghi L
Genes (Basel); 2023 May; 14(6):. PubMed ID: 37372349
[TBL] [Abstract][Full Text] [Related]
3. PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells.
Gutting T; Hauber V; Pahl J; Klapproth K; Wu W; Dobrota I; Herweck F; Reichling J; Helm L; Schroeder T; Li B; Weidner P; Zhan T; Eckardt M; Betge J; Belle S; Sticht C; Gaiser T; Boutros M; Ebert MPA; Cerwenka A; Burgermeister E
Oncoimmunology; 2021 May; 10(1):1906500. PubMed ID: 34026331
[TBL] [Abstract][Full Text] [Related]
4. Cholecystectomy and the risk of colorectal cancer by tumor mismatch repair deficiency status.
Shang J; Reece JC; Buchanan DD; Giles GG; Figueiredo JC; Casey G; Gallinger S; Thibodeau SN; Lindor NM; Newcomb PA; Potter JD; Baron JA; Hopper JL; Jenkins MA; Win AK
Int J Colorectal Dis; 2016 Aug; 31(8):1451-7. PubMed ID: 27286977
[TBL] [Abstract][Full Text] [Related]
5. Association of PD-L1 Expression with Clinicopathologic Characters in Gastric Cancer: A Comprehensive Meta-analysis.
Han Z; Wang N; Qiao Q; He X; Wang N
Curr Med Chem; 2023 Oct; ():. PubMed ID: 37921182
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the characteristics of coexisting lesions in colorectal cancer patients in an international study: A subgroup analysis of the ATLAS trial.
Yoshida N; Suzuki S; Inoue K; Aniwan S; Chiu HM; Laohavichitra K; Chirapongsathorn S; Yamamura T; Kuo CY; Ang TL; Takezawa T; Rerknimitr R; Ishikawa H;
Digestion; 2024 Apr; ():. PubMed ID: 38631318
[TBL] [Abstract][Full Text] [Related]
7. High Expression of MRE11A Is Associated with Shorter Survival and a Higher Risk of Death in CRC Patients.
Azambuja DB; E Gloria HC; Montenegro GES; Kalil AN; Hoffmann JS; Leguisamo NM; Saffi J
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372450
[TBL] [Abstract][Full Text] [Related]
8. Do Elevated YKL-40 Levels Drive the Immunosuppressive Tumor Microenvironment in Colorectal Cancer? Assessment of the Association of the Expression of YKL-40, MMP-8, IL17A, and PD-L1 with Coexisting Type 2 Diabetes, Obesity, and Active Smoking.
Ochman B; Mielcarska S; Kula A; Dawidowicz M; Robotycka J; Piecuch J; Szrot M; Dzięgielewska-Gęsiak S; Muc-Wierzgoń M; Waniczek D; Świętochowska E
Curr Issues Mol Biol; 2023 Mar; 45(4):2781-2797. PubMed ID: 37185706
[TBL] [Abstract][Full Text] [Related]
9. Review of Animal Models of Colorectal Cancer in Different Carcinogenesis Pathways.
Chen X; Ding Y; Yi Y; Chen Z; Fu J; Chang Y
Dig Dis Sci; 2024 May; 69(5):1583-1592. PubMed ID: 38526618
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy and radiotherapy for older patients with locally advanced rectal cancer unfit for surgery or decline surgery: a practical proposal by the International Geriatric Radiotherapy Group.
Nguyen NP; Mohammadianpanah M; SunMyint A; Page BR; Vinh-Hung V; Gorobets O; Arenas M; Mazibuko T; Giap H; Vasileiou M; Dutheil F; Tuscano C; Karlsson UL; Dahbi Z; Natoli E; Li E; Kim L; Oboite J; Oboite E; Bose S; Vuong T
Front Oncol; 2024; 14():1325610. PubMed ID: 38463223
[TBL] [Abstract][Full Text] [Related]
11. Sex Difference of Colon Adenoma Pathway and Colorectal Carcinogenesis.
Choi Y; Kim N
World J Mens Health; 2024 Apr; 42(2):256-282. PubMed ID: 37652658
[TBL] [Abstract][Full Text] [Related]
12. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
[TBL] [Abstract][Full Text] [Related]
13. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression.
Acosta-Gonzalez G; Ouseph M; Lombardo K; Lu S; Glickman J; Resnick MB
Hum Pathol; 2019 Jan; 83():115-123. PubMed ID: 30172913
[TBL] [Abstract][Full Text] [Related]
14. CD169
Saito Y; Fujiwara Y; Miyamoto Y; Ohnishi K; Nakashima Y; Tabata Y; Baba H; Komohara Y
Cancer Med; 2023 May; 12(9):10199-10211. PubMed ID: 36846928
[TBL] [Abstract][Full Text] [Related]
15. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.
Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z
Front Immunol; 2022; 13():1001444. PubMed ID: 36159842
[TBL] [Abstract][Full Text] [Related]
16. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
17. Influence of location-dependent sex difference on PD-L1, MMR/MSI, and EGFR in colorectal carcinogenesis.
Choi J; Kim N; Nam RH; Kim JW; Song CH; Na HY; Kang GH
PLoS One; 2023; 18(2):e0282017. PubMed ID: 36802389
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
